Vertex Pharma (VRTX) Tops Q1 EPS by 72c, Revenues Beat; Raises FY20 Revenues Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Vertex Pharma (VRTX) Granted European CHMP Positive Opinion for KALYDECO for Children/Adolescents with CF and R117H Mutation in CFTR Gene
May 1, 2020 5:50 AM EDTVertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that the European Medicines Agencys (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the label extension of KALYDECO® (ivacaftor), to include the treatment of children and adolescents with cystic fibrosis (CF), ages 6 months and older weighing at least 5 kg who have the R117H mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
Todays announcement is important for young people with CF, as early intervention and treatment of this devastating and progressive disease is key to... More
RBC Capital Downgrades Vertex (VRTX) to Sector Perform
April 28, 2020 5:12 AM EDTRBC Capital analyst Brian Abrahams downgraded Vertex (NASDAQ: VRTX) from Outperform to Sector Perform with a price target of $260.00 (from $250.00).
The analyst comments "We remain bullish on the company's fundamentals, with high growth prospects for its core cystic fibrosis franchise, strong adoption of launching drug Trikafta, good insulation from COVID-19 likely... More
Vertex Pharma (VRTX), Affinia Therapeutics Establish Multi-Year Collaboration to Discover and Develop Novel AAV Capsids for Genetic Therapies
April 27, 2020 8:32 AM EDTVertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Affinia Therapeutics announced today that the two companies have entered into a strategic research collaboration to engineer novel adeno-associated virus (AAV) capsids to deliver transformative genetic therapies to people with serious diseases. Affinia Therapeutics proprietary AAVSmartLibrary and associated technology provides capsids for improved tissue tropism, manufacturability and pre-existing immunity. The collaboration will leverage Affinia Therapeutics capsid engineering expertise and Vertexs scientific, clinical and regulatory capabilities to accelerate the development of genetic therapies for people affected by Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and cystic fibrosis (CF).
... More
